Peptides: what’s approved, what’s hype and what patients are injecting
“Peptides” now means two very different things: some of the most effective medicines of the decade (insulin, GLP-1s), and a grey market of vials labelled “for research use only” sold on social media. Patients increasingly ask about the second group, or are already using it. This is the evidence, the law in Australia and a safety script for the consult.
At a glance
- A peptide is just a short protein: usually 2 to 50 amino acids. Insulin (51), semaglutide, oxytocin and goserelin are all peptides. “Peptide” is not a marker of safety or naturalness.
- Approved peptides have outcome data: semaglutide 2.4 mg gave about 15% weight loss in STEP 1 and a 20% cut in major cardiovascular events in SELECT; tirzepatide about 21% in SURMOUNT-1.
- The popular grey-market peptides mostly don’t: a 2025 systematic review of BPC-157 found 35 animal studies, 1 human study (12 patients, retrospective) and no clinical safety data.
- Australia has acted: GLP-1 compounding was banned from 1 October 2024, and in June 2026 the Chief Medical Officer and TGA issued a joint warning on unapproved peptides, citing anaphylaxis, SIRS and liver injury.
- Oral collagen is safe but oversold: independent, high-quality RCTs show no skin benefit (meta-analysis of 23 RCTs, 2025).
- Sport: BPC-157 (S0), TB-500 and GH secretagogues (S2) are on the WADA prohibited list at all times.
Biggest take-home: ask every gym-goer, longevity enthusiast and weight-loss patient “any peptides or injections from online?” They often won’t volunteer it.
For patients: Collagen, GHK-Cu, GLP-1 medicines, Semaglutide, Tirzepatide, Creatine. For clinicians: the Type 2 diabetes deep dive (incretin pipeline).
Definition and chemistry
- Peptide: a chain of amino acids joined by peptide bonds. Convention: under about 50 amino acids is a peptide, above is a protein. Insulin sits on the line.
- Why most are injected: stomach acid and gut proteases digest them, and they cross membranes poorly. Oral semaglutide needs an absorption enhancer (SNAC) and still has about 1% bioavailability.
- Short half-lives: native GLP-1 lasts about 2 minutes; semaglutide’s fatty-acid side chain binds albumin, stretching it to about a week. BPC-157’s half-life is under 30 minutes in animal work.
- Collagen “peptides”: hydrolysed gelatin, eaten as food protein and digested to amino acids and di- or tri-peptides (such as hydroxyprolyl-glycine). Not comparable to injected signalling peptides.
Approved peptide medicines in Australia (the legitimate end)
- Metabolic: insulins; GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide); tirzepatide (GIP/GLP-1).
- Bone: teriparatide (PTH 1–34) for severe osteoporosis.
- Hormonal: goserelin and leuprorelin (GnRH analogues), oxytocin, desmopressin, octreotide and lanreotide (somatostatin analogues).
- Dermatology: afamelanotide implant (a melanocortin analogue) for erythropoietic protoporphyria, under specialist care. Melanotan II, its unapproved cousin, is a different product.
- Others: ciclosporin (cyclic peptide), vancomycin (glycopeptide), bivalirudin.
- Point for patients: these went through randomised trials, sterile manufacture and post-marketing surveillance. That process is what “approved” buys you, not the molecule type.
GLP-1s and the compounding story
- Efficacy: STEP 1 (n=1,961): semaglutide 2.4 mg weekly, −14.9% vs −2.4% weight at 68 weeks. SURMOUNT-1 (n=2,539): tirzepatide 15 mg, −20.9% at 72 weeks. SELECT (n=17,604, established CVD, no diabetes): MACE HR 0.80.
- Compounding: during shortages, compounded “semaglutide” (sometimes salt forms, variable strength) spread through telehealth. The TGA removed GLP-1 receptor agonists from compounding exemptions from 1 October 2024.
- Next wave: retatrutide (GIP/GLP-1/glucagon triple agonist, phase 2: −24.2% at 48 weeks) is unapproved but already sold online; Victoria has issued a health alert about toxicity from such products.
- Ask about: pen source, dose escalation, vomiting and dehydration (AKI), gallstones, pancreatitis, and contraception (oral contraceptive absorption with tirzepatide).
The grey-market peptides: evidence by product
- BPC-157 (“body protection compound”): a 15-amino-acid fragment from a gastric protein. Promoted for tendon, ligament and gut healing. Evidence: animal studies (mostly one research group) plus a retrospective series of 12 knee-pain patients (7 reported relief over 6 months) and a 2-person IV “safety” pilot. No RCTs. Theoretical concern: pro-angiogenic signalling in people with cancer. WADA S0.
- TB-500 (thymosin β4 fragment): promoted for injury recovery. Human data are limited to early trials of full-length thymosin β4 in wounds and eyes, not the fragment sold online. WADA S2.
- GH secretagogues (CJC-1295, ipamorelin, GHRP-2/6, sermorelin): raise growth hormone and IGF-1. No outcome data for “anti-ageing” or body composition in healthy adults; risks include fluid retention, insulin resistance and, theoretically, cancer promotion via IGF-1. Tesamorelin is approved overseas only for HIV lipodystrophy. WADA S2.
- Melanotan I and II (“tanning peptides”, nasal sprays): unapproved. Nausea, flushing, spontaneous erections and priapism, new or darkening moles; case reports of melanoma diagnosed after use. In Australia this is a skin-check conversation.
- GHK-Cu: reasonable as a topical cosmetic (small, mostly industry-linked studies); no human trials for injection. Named in the 2026 TGA warning.
- Thymosin α1, KPV, epitalon, “Selank/Semax”, MOTS-c, SS-31: mostly animal data, small foreign trials or none for the uses sold. Treat as unknown.
- Bremelanotide: FDA-approved for low sexual desire in premenopausal women; not approved in Australia.
Harms seen with unapproved peptides
- Product quality: “research use only” vials have no assurance of identity, dose, sterility or endotoxin testing; counterfeits mimic genuine pens.
- Australian reports (TGA, 2026): anaphylaxis requiring adrenaline, systemic inflammatory response syndrome, generalised hypersensitivity, liver injury, tendon problems (plantar fasciitis, Achilles tendinitis), insomnia and blurred vision.
- Injection risks: abscesses, cellulitis, and blood-borne virus risk with shared equipment. Reconstitution errors cause 10-fold dosing mistakes.
- Hidden ingredients: stacks may combine GH secretagogues, GLP-1 analogues and others, confusing the clinical picture.
- Sport: strict liability: a contaminated or mislabelled product still counts as a positive test.
The law in Australia (plain version)
- Unapproved peptides aren’t on the ARTG. Supplying, advertising or importing them without proper authority can be unlawful; prescription-only substances bought without a prescription are unlawful to obtain.
- Doctors can access unapproved medicines only through formal pathways (Special Access Scheme, Authorised Prescriber, clinical trials). A clinic selling “wellness peptides” off a website is not that.
- Compounding pharmacists can’t compound GLP-1 receptor agonists (from 1 October 2024).
- Suspected unlawful supply or advertising can be reported to the TGA; adverse events go to the TGA via the Report a side effect page.
Supplements patients call peptides
- Collagen: meta-analysis of 23 RCTs (1,474 participants): pooled benefit for hydration, elasticity and wrinkles disappeared in non-industry-funded and high-quality trials. Small joint and bone signals. Safe; an incomplete protein (no tryptophan). See Collagen.
- Creatine is an amino acid derivative, not a peptide, but sits in the same gym conversation: it has good evidence for strength with training and raises serum creatinine. See Creatine.
- Whey protein: a food protein; useful for hitting protein targets, especially in older adults doing resistance training.
A 2-minute consult script
- Ask: “Are you using any peptides, injections or nasal sprays bought online or from a clinic?” Ask what, dose, source and why.
- Acknowledge the goal (recovery, weight, skin, ageing) and offer what has evidence: rehab and loading for tendons; approved GLP-1s or tirzepatide for eligible weight loss; sunscreen and retinoids for skin; resistance training and protein for muscle.
- Safety advice if they continue: don’t share equipment; never inject cloudy or discoloured product; stop and seek care for rash, swelling, fever or breathing trouble; tell every doctor; skin check if they’ve used melanotan; avoid GH-axis peptides with any cancer history; athletes should check WADA status.
- Investigate if relevant: LFTs, glucose and HbA1c, IGF-1 (GH secretagogues), and a full skin check (melanotan).
- Report adverse events to the TGA.
Open questions
- Will any regenerative peptide (BPC-157, thymosin β4) be tested in a proper RCT? Interest from orthopaedic surgeons is rising, and trials are the only way out of the grey market.
- How common is peptide use in Australia? There are no prevalence data, only TGA reports and social media signals.
- Oral small-molecule GLP-1 agonists (such as orforglipron) may reduce demand for injectable grey-market products.
Key trials
- STEP 1 (Wilding 2021): semaglutide 2.4 mg, n=1,961, −14.9% vs −2.4%.
- SURMOUNT-1 (Jastreboff 2022): tirzepatide, n=2,539, up to −20.9%.
- SELECT (Lincoff 2023): semaglutide in CVD without diabetes, n=17,604, MACE HR 0.80.
- Retatrutide phase 2 (Jastreboff 2023): n=338, −24.2% at 48 weeks.
- Collagen meta-analysis (Myung 2025): 23 RCTs, no effect in independent or high-quality trials.
- BPC-157 systematic review (Vasireddi 2025): 36 studies, 35 preclinical.
Sources
- Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025;21:485–495
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025;31:20–24
- Myung SK, Park Y. Effects of collagen supplements on skin aging: systematic review and meta-analysis of RCTs. Am J Med 2025;138:1264–1277
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018
- Healthdirect. Peptides and your health in Australia: facts versus hype (2026)
- TGA. Concerns regarding public health risks associated with unapproved peptide products (2026)
- TGA. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products
- World Anti-Doping Agency. Prohibited List
- Sport Integrity Australia
Information only. Check product information, TGA guidance and current Australian law before acting. Don’t supply or recommend unapproved products.
maladywise.com/deep-dives/peptides/